Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2018

View Archived Issues

Dare Bioscience enters agreement with Pear Tree Pharmaceuticals to secure rights to PT-101

Durable antidepressive effect seen with ALKS-5461 in phase III trial

Novel serine palmitoyltransferase inhibitors identified at Takeda

Novartis describes novel IKACh channel blockers

Nektar Therapeutics initiates phase Ib trial of NKTR-358 in patients with SLE

Cellcentric divulges new KAT3 and/or CREB-binding protein inhibitors

Intravenous formulation of Akynzeo launched in the U.S.

New RIP-1 inhibitors discovered at Roche, Genentech

Merck & Co. patents lysine-specific demethylase 5B inhibitors

Bristol-Myers Squibb presents novel nuclear receptor ROR-gamma inverse agonists

CymaBay Therapeutics initiates phase IIb trial of seladelparin NASH

FDA clears Palladio to begin phase II study of lixivaptan in ADPKD

EMA approves Lynparza tablets for the treatment of platinum-sensitive relapsed ovarian cancer

Provention Bio partners with Intravacc to advance CVB vaccine PRV-101

MG7-CART therapy evaluated for the first time in a patient with metastatic colorectal cancer

Janssen Pharma launches Sirturo Tablets in Japan

Novo Nordisk reviews pipeline highlights of first quarter 2018

Alternative targeting of IDO pathway: New developments from the AAI annual meeting

Phase III TAGS trial of Lonsurf in metastatic gastric cancer meets primary endpoint

Researchers present INT-1B3 as a promising antitumoral compound

Atara Biotherapeutics expands collaboration with Memorial Sloan Kettering

Biohaven establishes expanded access program for sublingual BHV-0223 for ALS

Celgene presents highlights of first quarter 2018

Promising phase II results for TOP-1630 in dry eye syndrome

Alnylam achieves delivery of siRNA conjugates to CNS

XtalPi and Pfizer enter research collaboration

OncoSec Medical and Merck & Co. to collaborate on clinical trial

BDII-selective inhibitor ABBV-744 active against acute myelogenous leukemia, prostate cancer